LT3095484T - Calcitonin mimetics for treating diseases and disorders - Google Patents

Calcitonin mimetics for treating diseases and disorders

Info

Publication number
LT3095484T
LT3095484T LTEP16174260.6T LT16174260T LT3095484T LT 3095484 T LT3095484 T LT 3095484T LT 16174260 T LT16174260 T LT 16174260T LT 3095484 T LT3095484 T LT 3095484T
Authority
LT
Lithuania
Prior art keywords
disorders
treating diseases
calcitonin mimetics
calcitonin
mimetics
Prior art date
Application number
LTEP16174260.6T
Other languages
Lithuanian (lt)
Inventor
Nozer M. Mehta
William Stern
Amy M. Sturmer
Morten Asser Karsdal
Kim Henriksen
Original Assignee
Keybioscience Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Keybioscience Ag filed Critical Keybioscience Ag
Publication of LT3095484T publication Critical patent/LT3095484T/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/23—Calcitonins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/585—Calcitonins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/64—Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
LTEP16174260.6T 2011-11-02 2012-11-02 Calcitonin mimetics for treating diseases and disorders LT3095484T (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161554771P 2011-11-02 2011-11-02
US201161578620P 2011-12-21 2011-12-21

Publications (1)

Publication Number Publication Date
LT3095484T true LT3095484T (en) 2018-08-10

Family

ID=51266018

Family Applications (1)

Application Number Title Priority Date Filing Date
LTEP16174260.6T LT3095484T (en) 2011-11-02 2012-11-02 Calcitonin mimetics for treating diseases and disorders

Country Status (12)

Country Link
EP (3) EP3095484B1 (en)
CY (1) CY1120332T1 (en)
DK (2) DK3095484T3 (en)
ES (2) ES2586805T3 (en)
HR (1) HRP20180903T1 (en)
HU (1) HUE039105T2 (en)
LT (1) LT3095484T (en)
PL (1) PL3095484T3 (en)
PT (1) PT3095484T (en)
RS (1) RS57519B1 (en)
SI (1) SI3095484T1 (en)
TR (1) TR201808456T4 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201704429D0 (en) * 2017-03-21 2017-05-03 Keybioscience Ag Calcitonin mimetics for treating diseases and disorders
GB201813678D0 (en) * 2018-08-22 2018-10-03 Keybioscience Ag Acylated calcitonin mimetics

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4708934A (en) 1984-09-27 1987-11-24 Unigene Laboratories, Inc. α-amidation enzyme
US6319685B1 (en) 1984-09-27 2001-11-20 Unigene Laboratories, Inc. Alpha-amidating enzyme compositions and processes for their production and use
US4764589A (en) * 1987-05-26 1988-08-16 Rorer Pharmaceutical Corporation [N-alpha-acyl,8-glycine, des-19-leucine]-calcitonin
US5789234A (en) 1987-08-14 1998-08-04 Unigene Laboratories, Inc. Expression systems for amidating enzyme
US5102666A (en) 1990-09-11 1992-04-07 Oramed, Inc. Calcium polycarbophil controlled release composition and method
US5359030A (en) 1993-05-10 1994-10-25 Protein Delivery, Inc. Conjugation-stabilized polypeptide compositions, therapeutic delivery and diagnostic formulations comprising same, and method of making and using the same
US6692766B1 (en) 1994-06-15 2004-02-17 Yissum Research Development Company Of The Hebrew University Of Jerusalem Controlled release oral drug delivery system
US5866536A (en) 1995-03-31 1999-02-02 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US5912014A (en) 1996-03-15 1999-06-15 Unigene Laboratories, Inc. Oral salmon calcitonin pharmaceutical products
US5773647A (en) 1997-02-07 1998-06-30 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
HUP0001272A3 (en) 1997-04-16 2012-12-28 Unigene Lab Inc Direct expression of peptides into culture media
CN1329502A (en) 1998-12-04 2002-01-02 普罗瓦利斯英国有限公司 Pharmaceutical compositions containing insulin
IL145546A0 (en) 1999-04-05 2002-06-30 Emisphere Tech Inc Disodium salts, monohydrates, and ethanol solvates for delivering active agents
US6780846B1 (en) 1999-09-27 2004-08-24 Elan Corporation, Plc Membrane translocating peptide drug delivery system
GB2368792A (en) 2000-10-06 2002-05-15 Roger Randal Charles New Absorption enhancers
US6673574B2 (en) 2000-11-30 2004-01-06 Unigene Laboratories Inc. Oral delivery of peptides using enzyme-cleavable membrane translocators
US7316819B2 (en) 2001-03-08 2008-01-08 Unigene Laboratories, Inc. Oral peptide pharmaceutical dosage form and method of production
US6770625B2 (en) 2001-09-07 2004-08-03 Nobex Corporation Pharmaceutical compositions of calcitonin drug-oligomer conjugates and methods of treating diseases therewith
JP2006521366A (en) 2003-03-28 2006-09-21 シグモイド・バイオテクノロジーズ・リミテッド Solid oral dosage forms containing seamless microcapsules
GB0308732D0 (en) 2003-04-15 2003-05-21 Axcess Ltd Absorption enhancers
PL1651249T3 (en) 2003-07-23 2013-04-30 Novartis Ag Use of calcitonin in osteoarthritis
EP1670500A2 (en) 2003-09-17 2006-06-21 Chiasma, Ltd. Compositions capable of facilitating penetration across a biological barrier
JP2008506750A (en) 2004-07-22 2008-03-06 ティオマトリックス・フォルシュンクス・ウント・べラートゥンクス・ゲーエムベーハー Use of compounds containing thiol groups as exhaust pump inhibitors
GB0422644D0 (en) * 2004-10-12 2004-11-10 Novartis Ag Organic compounds
US7445911B2 (en) 2004-11-24 2008-11-04 Unigene Laboratories Inc. Enzymatic reactions in the presence of keto acids
EP1907561B1 (en) 2005-06-24 2013-08-28 Unigene Laboratories, Inc. Cell lines for expressing enzyme useful in the preparation of amidated products
JP5222727B2 (en) 2005-09-06 2013-06-26 オーラメッド・ファーマスーティカルズ・インコーポレイテッド Methods and compositions for oral administration of proteins
US8093207B2 (en) 2005-12-09 2012-01-10 Unigene Laboratories, Inc. Fast-acting oral peptide pharmaceutical products
PT1834635E (en) 2006-03-13 2011-10-13 Advanced In Vitro Cell Technologies S L Stable nanocapsule systems for the administration of active molecules
CA2648594C (en) 2006-04-07 2012-10-16 Merrion Research Iii Limited Solid oral dosage form containing an enhancer
US8377863B2 (en) 2007-05-29 2013-02-19 Unigene Laboratories Inc. Peptide pharmaceutical for oral delivery
US8962015B2 (en) 2007-09-28 2015-02-24 Sdg, Inc. Orally bioavailable lipid-based constructs
WO2010085700A2 (en) * 2009-01-22 2010-07-29 Unigene Laboratories Inc. Treatment for obesity
NZ595021A (en) * 2009-03-12 2013-04-26 Nordic Bioscience As Treatment of diabetes and metabolic syndrome with enteral formulations of calcitonin peptides or calcitonin receptor agonists

Also Published As

Publication number Publication date
PL3095484T3 (en) 2018-10-31
EP3357540A1 (en) 2018-08-08
EP2773365A4 (en) 2015-05-20
EP2773365B1 (en) 2016-07-20
ES2673617T3 (en) 2018-06-25
PT3095484T (en) 2018-06-20
HRP20180903T1 (en) 2018-08-24
ES2586805T3 (en) 2016-10-19
HUE039105T2 (en) 2018-12-28
RS57519B1 (en) 2018-10-31
TR201808456T4 (en) 2018-07-23
EP3095484B1 (en) 2018-05-02
SI3095484T1 (en) 2018-08-31
CY1120332T1 (en) 2019-07-10
DK3095484T3 (en) 2018-06-25
EP2773365A1 (en) 2014-09-10
EP3095484A1 (en) 2016-11-23
DK2773365T3 (en) 2016-08-29

Similar Documents

Publication Publication Date Title
HRP20190356T1 (en) Calcitonin mimetics for treating diseases and disorders
HK1215375A1 (en) Use of akkermansia for treating metabolic disorders
GB2492487B (en) Cannabinoids for use in the treatment of neurodegenerative diseases or disorders
HK1210968A1 (en) Compositions and treatment for eye diseases and disorders
HK1207860A1 (en) 2-phenyl-5-heterocyclyl-tetrahydro-2h-pyran-3-amine compounds for use in the treatment of diabetes and its associated disorders 2--5---2h--3-
PL2919796T3 (en) Use of akkermansia for treating metabolic disorders
HK1219224A1 (en) Therapeutic agent for keratoconjunctive disorders
EP2723339A4 (en) Compounds for treating peripheral neuropathies and other neurodegenerative disorders
ZA201308176B (en) Therapeutic treatment
PL3095484T3 (en) Calcitonin mimetics for treating diseases and disorders
GB201217330D0 (en) Therapeutic for treating inflammatory lung disorders
GB201320112D0 (en) Calcitonin Mimetics for treating diseases and disorders
GB201101183D0 (en) Treatment of neurodegenerative disorders